THIS ANNOUNCEMENT (THE "ANNOUNCEMENT"), AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN MOLECULAR ENERGIES PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH, ANY INVESTMENT DECISION IN RESPECT OF MOLECULAR ENERGIES PLC.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU NO. 596/2014) AS IT FORMS PART OF
MOLECULAR ENERGIES PLC
("Molecular" or the "Company")
Result of Fundraising
Molecular Energies (AIM: MEN), the international energy company, is pleased to announce that, further to the announcement made at 7.00 a.m. on 24 January 2024 (the "ABB Announcement") it has successfully raised
Capitalised terms in the announcement shall have the same meaning ascribed to them as in the ABB Announcement unless the context requires otherwise.
Cavendish Capital Markets Limited ("Cavendish") acted as bookrunner to the Placing.
ADMISSION
The Company is issuing 1,852,824 New Ordinary Shares pursuant to the Placing and Subscription, representing 17.9 per cent. of the Company's issued share capital at the date of this Announcement. The Company has the authority to issue and allot the New Ordinary Shares pursuant to certain existing shareholder authorities granting such powers to the directors at the Company's Annual General Meeting held on 21 September 2023.
The New Ordinary Shares will, when issued, be credited as fully paid up and will be issued subject to the Articles and rank pari passu in all respects with the Company's existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid on or in respect of the Ordinary Shares after the date of issue of the New Ordinary Shares, and will on issue be free of all claims, liens, charges, encumbrances and equities.
Application has been made to the London Stock Exchange for the admission of the New Ordinary Shares to trading on AIM ("Admission"). It is expected that Admission will occur on or around 8.00 a.m. on 26 January 2024.
Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 12,218,197 with each Ordinary Share carrying the right to one vote. There are no Ordinary Shares held in treasury and therefore the total number of voting rights in the Company is 12,218,197. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
For more information, please visit www.molecularenergiesplc.com or contact:
Molecular Energies PLC Peter Levine, Chairman Rob Shepherd, Group FD
|
+44 (0)20 7016 7950 |
Cavendish Capital Markets Limited (Nominated Adviser & Broker) Simon Hicks, George Dollemore
|
+44 (0)20 7220 0500 |
Tavistock (Financial PR & IR) Simon Hudson, Nick Elwes, Charles Baister |
+44 (0)20 7920 3150 |
This Announcement is released by Molecular Energies plc and contains inside information for the purposes of Article 7 of MAR, and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
Market soundings (as defined in MAR) were taken in respect of the Placing with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR. This inside information is set out in this Announcement. Therefore, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities.
For the purposes of MAR, Article 2 of Commission Implementing Regulation (EU) 2016/1055 and the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.